Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jun 30, 2026

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Published on: August 19, 2025

Intraoperative Radiotherapy for Breast Cancer: Long-Term Experience.

Shlomit Fennig^1,2, Anna Kirshtein^3,4, Yosef Landman^5,4

¹Institute of Oncology, Kaplan Medical Center, Rehovot, Israel.

Annals of Surgical Oncology

|June 29, 2026

Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Favorable safety outcomes of a perioperative propranolol and etodolac regimen in cancer patients in four randomized controlled trials.

Frontiers in pharmacology·2026

Same author

Removal of radiation-related tattoos among breast cancer survivors using a 20-nanosecond Q-switched Ruby laser.

Lasers in medical science·2026

Same author

4D printing of fully programmable sheets of digital metamaterials.

Soft matter·2026

Same author

Sun-Exposed vs. Non-Sun-Exposed Areas: Epidemiology and Pathogenesis of Non-Metastatic Merkel Cell Carcinoma.

Diagnostics (Basel, Switzerland)·2026

Same author

Hard and Soft MRI Signs of Nipple-Areolar Complex Involvement in Breast Cancer.

Clinical breast cancer·2026

Same author

Complicated Appendicitis in a Universal Healthcare System: Do Ethnic Disparities Persist?

Health care analysis : HCA : journal of health philosophy and policy·2026

Same journal

Lymph Node Yield and Disease-Free Survival After Neoadjuvant Chemoimmunotherapy for Esophageal Squamous Cell Carcinoma: A Multicenter, Retrospective Cohort Study.

Annals of surgical oncology·2026

Same journal

The Role of Surgery on the Treatment of Primary Pulmonary Sarcomas and Pulmonary Sarcomatoid Carcinoma.

Annals of surgical oncology·2026

Same journal

ASO Visual Abstract: Revisiting the Concept of Nerve-Sparing Radical Hysterectomy: A Proof-of-Concept Prospective Study from a Cervical Cancer Cohort.

Annals of surgical oncology·2026

Same journal

ASO Visual Abstract: Sentinel Node Biopsy in the Neck Management of cN0 Sinonasal Squamous Cell Carcinoma-A Multicenter Pilot Trial on Safety and Feasibility.

Annals of surgical oncology·2026

Same journal

ASO Visual Abstract: High Prevalence of Clinical Understaging in Early Gastric Cancer: An Analysis of the NCDB.

Annals of surgical oncology·2026

Same journal

ASO Author Reflections: Looking Beyond Imaging-Multimodal Response Assessment after Modern Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma.

Annals of surgical oncology·2026

See all related articles

This summary is machine-generated.

Targeted intraoperative radiation therapy (TARGIT-IORT) offers excellent local control and high survival rates for low-risk early breast cancer. This single-dose radiation therapy shows a very low toxicity profile, making it a suitable option for select patients.

Area of Science:

Oncology
Radiation Oncology
Surgical Oncology

Background:

Targeted intraoperative radiation therapy (TARGIT-IORT) is an alternative to whole-breast external beam radiation for early-stage breast cancer.
Current guidelines restrict TARGIT-IORT use, necessitating long-term outcome data in specific patient populations.
This study evaluates long-term results of TARGIT-IORT in a carefully selected group of early breast cancer patients.

Purpose of the Study:

To present long-term outcomes of TARGIT-IORT in a restricted population of early-stage breast cancer patients.
To assess the efficacy and safety of TARGIT-IORT as a treatment option.
To provide evidence supporting the use of TARGIT-IORT in suitable candidates.

Main Methods:

Retrospective search of electronic records for women diagnosed with invasive ductal carcinoma (2014-2023).

Keywords:

Breast cancer Intraoperative radiation therapy Local recurrence Partial breast irradiation Whole breast radiotherapy

More Related Videos

Stereotactic Radiosurgery for Gynecologic Cancer

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

Related Experiment Videos

Last Updated: Jun 30, 2026

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Published on: August 19, 2025

Stereotactic Radiosurgery for Gynecologic Cancer

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

Inclusion criteria: age >50, unifocal disease, tumor size <3 cm, ER-positive, HER2-non-amplified.

TARGIT-IORT (20 Gy single dose) delivered via applicator post-lumpectomy and SLNB, followed by clinical and imaging follow-up.

Main Results:

219 patients included (median age 66 years).
Median follow-up of 85 months revealed low recurrence rates: 0.45% ipsilateral breast, 0.45% axillary lymph node, and 0.45% liver metastasis.
Low toxicity: 9.1% minor wound complications, 1.4% fat necrosis, all self-limiting.

Conclusions:

TARGIT-IORT demonstrates excellent local control and high survival rates in low-risk early breast cancer.
The treatment exhibits a very low toxicity profile, consistent with previous trial data.
TARGIT-IORT should be considered for suitable patients with early-stage, low-risk breast cancer.